Director/PDMR Shareholding

RNS Number : 2548O

Dechra Pharmaceuticals PLC

06 October 2021

 

6 October 2021

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

Dechra Pharmaceuticals PLC announces that on 5 October 2021,   Paul Sandland, Executive Director and PDMR exercised market value options over ordinary shares of 1p each in the Company. The options were granted under the Dechra Pharmaceuticals 2017 Long Term Incentive Plan as detailed below before Paul Sandland's appointment as an Executive Director. The exercise of the options was subject to the achievement of performance conditions which were satisfied to the extent that the options vested at 100%. Paul Sandland sold 3,960 of the shares acquired to fund the exercise prices and tax liabilities arising in connection with the exercises of the unapproved share options, and retained the remaining 2,040 shares. 

Date of Grant	Scheme	Number of options exercised	Option Price	Number of shares sold	Sale Price
2 March 2018	Approved	550	£25.06	Nil	N/A
2 March 2018	Unapproved	2,450	£25.06	1,830	£48.285
26 October 2018	Unapproved	3,000	£21.66	2,130	£48.285

Paul Sandland's total beneficial holding following these transactions is 9,651 ordinary shares which represents 0.009% of the total issued share capital.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK  Market Abuse Regulation.

Notification of Dealing Forms

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/Chief Financial Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Exercise of options under the Company's 2017 Long Term Incentive Plan (Approved Options)
c)	Price(s) and volumes(s)	Price(s) £25.06	Volume(s) 550
d)	Aggregated information -  Aggregate volume -  Price -  Total	550 £25.06 £13,783.00
e)	Date of the transaction	2021.10.05
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/Chief Financial Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Exercise of options under the Company's 2017 Long Term Incentive Plan (Unapproved Options)
c)	Price(s) and volumes(s)	Price(s) £25.06 £21.66	Volume(s) 2,450 3,000
d)	Aggregated information -  Aggregate volume -  Price -  Total	5,450 £23.188 £126,377.00
e)	Date of the transaction	2021.10.05
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/Chief Financial Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Sale of shares obtained under the Company's 2017 Long Term Incentive Plan (Unapproved Options)
c)	Price(s) and volumes(s)	Price(s) £ 48.285	Volume(s) 3,960
d)	Aggregated information -  Aggregate volume -  Price -  Total	3,960 £ 48.285 £191,208.60
e)	Date of the transaction	2021.10.05
f)	Place of the transaction	London Stock Exchange

For further information, please contact:

Melanie Hall, Company Secretary 

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

DSHBSBDGIXGDGBL